Evidence map›Paper›PMID 24524409›Full record

ArticleMolecular pharmaceutics2014

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Xiaohua Zhu, Jinbo Li, Yeongjin Hong, Richard H Kimura, Xiaowei Ma, Hongguang Liu, Chunxia Qin, Xiang Hu, Thomas R Hayes, Paul Benny and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Pre-clinical SPECT and SPECT-CT in Oncology.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Article
  4. Cancers · 2025
    Review
  5. Review
  6. Review
  7. Integrin αCancer imaging : the official publication of the International Cancer Imaging Society · 2021
    Article
  8. Article
  9. Clinical Translation of aJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  10. Article
  11. PET/CT Imaging of NSCLC with a αMolecular imaging and biology · 2019
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Cyclotides: Overview and Biotechnological Applications.Chembiochem : a European journal of chemical biology · 2017
    Review
  18. Article
  19. Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017
    Article
  20. Plant cystine-knot peptides: pharmacological perspectives.British journal of clinical pharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Xiaohua ZhuMolecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University , Stanford, California 94305-5344, United States.
Jinbo Li
Yeongjin Hong
Richard H Kimura
Xiaowei Ma
Hongguang Liu
Chunxia Qin
Xiang Hu
Thomas R Hayes
Paul Benny
Sanjiv Sam Gambhir
Zhen Cheng
Stanford University · USWashington State University · USTongji Hospital · CN

Funding

Small Animal ImagingP50CA114747 · NCI · STANFORD UNIVERSITY · PI RAO, JIANGHONG · 2005 to 2014
$18.2M
NCI NIH HHS P50 CA114747
6 · The paper itself

Abstract

Integrin αvβ6 is overexpressed in a variety of cancers, and its expression is often associated with poor prognosis. Therefore, there is a need to develop affinity reagents for noninvasive imaging of integrin αvβ6 expression since it may provide early cancer diagnosis, more accurate prognosis, and better treatment planning. We recently engineered and validated highly stable cystine knot peptides that selectively bind integrin αvβ6 with no cross-reactivity to integrins αvβ5, α5β1, or αvβ3, also known to be overexpressed in many cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging integrin αvβ6 positive tumors. Cystine knot peptide, S02, was first conjugated with a single amino acid chelate (SAAC) and labeled with [(99m)Tc(H2O)3(CO)3](+). The resulting probe, (99m)Tc-SAAC-S02, was then evaluated by in vitro cell uptake studies using two αvβ6 positive cell lines (human lung adenocarcinoma cell line HCC4006 and pancreatic cancer cell line BxPC-3) and two αvβ6 negative cell lines (human lung adenocarcinoma cell line H838 and human embryonic kidney cell line 293T). Next, SPECT/CT and biodistribution studies were performed in nude mice bearing HCC4006 and H838 tumor xenografts to evaluate the in vivo performance of (99m)Tc-SAAC-S02. Significant differences in the uptake of (99m)Tc-SAAC-S02 were observed in αvβ6 positive vs negative cells (P < 0.05). Biodistribution and small animal SPECT/CT studies revealed that (99m)Tc-SAAC-S02 accumulated to moderate levels in antigen positive tumors (∼2% ID/g at 1 and 6 h postinjection, n = 3 or 4/group). Moreover, the probe demonstrated tumor-to-background tissue ratios of 6.81 ± 2.32 (tumor-to-muscle) and 1.63 ± 0.18 (tumor-to-blood) at 6 h postinjection in αvβ6 positive tumor xenografts. Co-incubation of the probe with excess amount of unlabeled S02 as a blocking agent demonstrated significantly reduced tumor uptake, which is consistent with specific binding to the target. Renal filtration was the main route of clearance. In conclusion, knottin peptides are excellent scaffolds for which to develop highly stable imaging probes for a variety of oncological targets. (99m)Tc-SAAC-S02 demonstrates promise for use as a SPECT agent to image integrin αvβ6 expression in living systems.

Indexed as

Cystine Knot MotifsOrganotechnetium CompoundsPeptidesRadiopharmaceuticalsAmino Acid SequenceAnimalsAntigens, NeoplasmCell Line, TumorFemaleHumansIntegrinsMiceMolecular Sequence DataNeoplasms, ExperimentalTissue DistributionTomography, Emission-Computed, Single-PhotonAntigens, Neoplasmintegrin alphavbeta6IntegrinsOrganotechnetium CompoundsPeptidesRadiopharmaceuticals

Identifiers

PMID24524409
PMCPMC3993876
OpenAlexW1215646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.